Metrics beyond HbA1c such as glucose variability are emerging as key parameters that can help guide the daily management of diabetes, but what is the clinical relevance of such measures, particularly for those with diabetes taking basal insulin?Our host, Dr. Ronald Goldenberg, takes a deeper look into this topic with Dr. Tadej Battelino, Professor, Head, and Chair of Pediatrics at the University of Ljubljana Faculty of Medicine, and Head of the Department of Pediatric and Adolescent Endocrinology at the UMC Ljubljana.There has been limited data on the utility of CGM as an outcome measure in clinical practice and a lack of evidence on the use of CGM to compare second-generation basal insulin analogues glargine 300 U/mL (Gla-300) and degludec 100 U/mL (IDeg-100). InRange was the first randomized controlled trial to compare Gla-300 and IDeg-100 in adults with type 1 diabetes using CGM data to assess time-in-range (TIR) as the primary endpoint.This episode discusses the within-day and between-day glucose variability data from the InRange study comparing Gla-300 and IDeg-100, of which Dr. Battelino was the primary investigator. Our experts also dive into the topics of why glucose variability should be a parameter of greater consideration, with a focus on coefficient of variation.Don’t miss the conversation!The views and opinions expressed in this episode are those of the speakers and do not necessarily reflect the views or positions of any entities they represent.Declaration of conflict of interest:Dr. Goldenberg:Direct financial relationship including receipt of honoraria: Abbott, Agora, Amgen, Antibody, AstraZeneca, Bayer, Boehringer Ingelheim, CCRN, CMSKTRG, Eli Lilly, EOCI, HIT Global, HLS, Inceptus, Janssen, LiV, Master Clinician Alliance, MD Briefcase, Merck, Mylan, Novo Nordisk, Sanofi, Script Medical, Servier, STA, Takeda, Toronto Knowledge Translation Working Group, Unik, Valeant. Membership on advisory boards or speaker’s bureau: Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, HLS, Janssen, Merck, Novo Nordisk, Sanofi. Funded grants, research or clinical trials: Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Novo Nordisk, Sanofi. Dr. Battelino:Membership on advisory boards or speaker’s bureau: Novo Nordisk, Sanofi, Eli Lilly, Boehringer-Ingelheim, Medtronic, Indigo Diabetes, AstraZeneca, Sanofi, Roche. Funded grants, research or clinical trials: Abbott Diabetes Care, Medtronic, Novo Nordisk, Sanofi, Sandoz, Novartis. Other financial relationships/investments: owns stocks of DreaMed Diabetes.

Ver todos los episodios